B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30

B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $29 to $30.